Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Brief Summary: This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification.

In addition, there is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in participants with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.


Options:
A: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
B: Arm Label: PF-02341066; Type: EXPERIMENTAL; Interventions: Drug: PF-02341066 | Arm Label: Pemetrexed or Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Docetaxel | Intervention Type: DRUG; Name: PF-02341066; Assigned to Arm(s): PF-02341066 | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed or Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pemetrexed or Docetaxel
C: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
D: Arm Label: Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Depatuxizumab mafodotin, Radiation: Radiation | Arm Label: Placebo, Radiation and TMZ; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation, Drug: Placebo for ABT-414 | Arm Label: Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Depatuxizumab mafodotin, Radiation: Radiation | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ, Placebo, Radiation and TMZ | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ, Placebo, Radiation and TMZ | Intervention Type: DRUG; Name: Placebo for ABT-414; Assigned to Arm(s): Placebo, Radiation and TMZ

Answer: D